What is Biotest AG (BIESF)?

Biotest AG (BIESF) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of BIESF?

The current price of BIESF is $32.00. Prices are updated in real time on Stocks360.

What is BIESF's price-to-earnings (PE) ratio?

BIESF's trailing twelve-month PE ratio is -16.08, based on current price and earnings per share data available on Stocks360.

What is BIESF's market capitalization?

BIESF's market capitalization is $1,599,788,800.00, placing it in the small-cap tier.

Does BIESF pay a dividend?

Yes. BIESF has a trailing twelve-month dividend yield of 0.00%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Biotest AG (BIESF)

Stock analysis · OTC · Healthcare · Biotechnology

$32.00

Market Cap

$1.60B

PE (TTM)

-16.08

EPS (TTM)

N/A

Dividend Yield

0.14%

Beta

0.17

Day Range

$32.00 – $32.00

52-wk Range

$30.48 – $32.00

Avg Volume

N/A

Volume

100.00

Biotest AG (BIESF) is a publicly traded company in the Healthcare sector. Latest price: $32.00. Market cap $1.60B. Trailing PE -16.08. Dividend yield 0.14%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Mar 24, 2015

EPS $-0.00 vs est. $0.22

Missed by $0.22

Proprietary Signals

Signal snapshot temporarily unavailable.

About Biotest AG

Biotest Aktiengesellschaft, a German biopharmaceutical company established in Dreieich in 1946, specializes in the research, development, production, and global commercialization of advanced biological therapeutics. Its operations are organized into key segments: Therapy, Plasma & Services, and Other. The company’s primary focus areas encompass critical medical needs within hematology (blood disorders), clinical immunology, and intensive care medicine. Biotest offers a comprehensive range of products, including specific treatments for hemophilia like Haemoctin and Vihuma for the acute and prophylactic management of hemophilia A, and Haemonine for similar applications in hemophilia B. Its portfolio also features immunotherapies such as Cytotect CP biotest for cytomegalovirus infections, Fovepta for hepatitis B prophylaxis in neonates, and Hepatect for preventing hepatitis B reinfection. Varitect addresses varicella zoster virus infections, while Intratect and IgG Next Generation are utilized for primary immune and secondary antibody deficiency syndromes, autoimmune conditions, and certain neurological indications. Additionally, Zutectra is available for hepatitis B re-infection pro…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-16.08×
P/S (TTM)	2.22×
P/B	2.46×
PEG	0.14×
P/FCF (TTM)	-9.29×
EV / EBITDA	-225.25×
EV / Sales	3.33×
Earnings Yield	-6.21%
Free Cash Flow Yield	-10.76%
Dividend Yield	0.14%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$2.16B
Revenue (TTM)	$648.66M
Net Income (TTM)	-$89.29M
Free Cash Flow (TTM)	-$124.94M
Net Debt	$722.93M
Working Capital	$718.23M
Gross Margin	9.54%
Operating Margin	-7.49%
Net Margin	-10.90%
Return on Equity	-14.22%
Return on Invested Capital	-2.61%